drugset / Trial / NCT01437826

Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial

NCT01437826

RandomizedParallel-groupDouble-blindPrevention

Summary

The trial was aimed at evaluating the efficacy of a multiagent antioxidant compound (vitamin A, C, E, selenium and zinc) in reducing the incidence of metachronous adenomas of the large bowel after endoscopic polypectomy. This is a randomized study: a 50% reduction in the incidence of metachronous adenomas was expected in patients allocated to the "active" compound (intervention) arm as compared to those assigned to a placebo.

Timeline

Start
1988-03
Primary completion
1996-06
Completion
1996-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Selenium Other / unclassified 200 ug
Subject Vitamin A Unknown 2 mg
Subject Vitamin C Other / unclassified 180 mg
Subject Vitamin E Other / unclassified 30 mg
Subject Zinc Sulfate Unknown 30 mg

Indications